In an interview, Wayne Luan, senior director, life sciences and provider solutions with Turquoise Health, told MedCity News Editor-in-Chief Arundhati Parmar that the company's platform provides pricing data for medical services, medical devices, and pharmaceutical drugs.
Growing use of wearable technologies and the data they produce was discussed by a panel at the MedCity News INVEST Digital Health Conference in Dallas.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Why should Medicare determine who is qualified to provide remote monitoring by asking who employs the nurse, rather than who is accountable for the patient's care?
Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response.
The FDA recently published draft guidance on pre-market testing for robotically-assisted surgical devices, raising timely discussion around whether hospital infrastructures are capable of supporting increasingly complex systems.
The FDA is recruiting to fill vacancies on its advisory committees, informally known as adcomms. While these committees have met less frequently during the Trump administration, more meetings have been scheduled since former Commissioner Marty Makary left the agency in May.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.
Today, 3D modeling and printing technology can make a dramatic impact — even shortening some operations by 30-90 minutes. Looking ahead, that reduction will only grow as the technology is further integrated and becomes more advanced.
Non-surgical implantable BCI is increasingly capable of matching surgical performance while transforming the risk-benefit equation, and it is now the most credible path along all three dimensions simultaneously.
The evolution of patient-matched medical devices represents more than just innovation in manufacturing and design. It marks a shift in clinical philosophy. Instead of shaping patients to fit implants, clinicians and device developers are harnessing technology to shape treatments around the individual.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
These products have yet to offer treatment solutions designed to get users from their current health state to a desired future health state. This creates a massive, untapped opening for tools that move people from awareness to action in a clinically meaningful way, without the cost and access barriers of engaging the healthcare system or requiring a prescription.
For consumers and clinicians the difference between “FDA-cleared,” “FDA-registered,” and general wellness products is not always obvious. Clear communication about intended use and supporting evidence is essential for maintaining trust.
If CMS and private payers are serious about whole-person health, reimbursement structures must align with the workforce actually delivering that care. Payment pathways should recognize the value of the broader care team and enable the seamless integration of their expertise with the objective data generated through connected devices and programs like RPM.
For patients, recalls can fail to protect them — not because they came too late, but because they stop at notification and never fully translate into action.
For providers, the rules mean more control over monitoring and the chance to keep a larger share of reimbursement. For device companies, they create a chance to show measurable value and guide clinicians through a system that is shifting quickly.